Loading...
Loading...
Jefferies & Company has downgraded Genzyme
GENZ from Buy to Hold and maintains its $80 price target.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: DowngradesPrice TargetAnalyst RatingsBiotechnologyGenzyme CorporationHealth CareJefferies & Company
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in